[68Ga]Ga-interleukin-2 for imaging activated T-lymphocytes: biochemical characterization and phase I study in normal subjects

This study aimed to develop a ready-to-use kit for Ga-labelling of interleukin-2 (IL2) facilitating PET imaging of activated T-lymphocytes. Human recombinant IL2 (hrIL2) and Aldesleukin (desIL2), conjugated with two different chelators (NODAGA and THP) were compared. Conjugated-IL2 was stored, freez...

Full description

Saved in:
Bibliographic Details
Published inEuropean journal of nuclear medicine and molecular imaging
Main Authors Signore, Alberto, Galli, Filippo, Varani, Michela, Campagna, Giuseppe, Bentivoglio, Valeria, Accardo, Antonella, Morelli, Giancarlo, Lauri, Chiara
Format Journal Article
LanguageEnglish
Published Germany 01.07.2025
Subjects
Online AccessGet full text

Cover

Loading…
Abstract This study aimed to develop a ready-to-use kit for Ga-labelling of interleukin-2 (IL2) facilitating PET imaging of activated T-lymphocytes. Human recombinant IL2 (hrIL2) and Aldesleukin (desIL2), conjugated with two different chelators (NODAGA and THP) were compared. Conjugated-IL2 was stored, freeze-dried at -80 °C and radiolabelled at room temperature. In vitro quality controls (iTLC, HPLC, SDS-PAGE, spectrometry and binding assays on activated T-lymphocytes) and in vivo biodistribution studies in BALB/c mice, were performed. The shelf life of the lyophilized kits was assessed up to 6 months of storage, by iTLC, HPLC and SDS-PAGE. First-in-human study was conducted in 5 volunteers by performing [ Ga]Ga-THP-desIL2 PET/CT acquisitions at several time-points, to assess biodistribution and dosimetry. Mass spectrometry showed that only one molecule of THP or NODAGA is bound to N-terminus of both IL2 proteins. The most efficient conjugation was observed for THP-desIL2. [ Ga]Ga-THP-desIL2 showed higher labelling yield (LY) (59.13 ± 2.58%), radiochemical purity (RCP) (97.91 ± 0.45%) and binding affinity to its receptor on activated T-cells (Kd = 0.584 nM/L) and a more favorable biodistribution in pre-clinical studies, with rapid kidney metabolism and lower liver uptake than [ Ga]Ga-NODAGA-desIL2 and [ Ga]Ga-THP-hrIL2. Lyophilized kit of THP-desIL2 remained stable at -80 °C up to 6 months maintaining high RCP and LY. Phase I study showed a rapid plasma clearance, renal metabolism, safety and favorable dosimetry. We developed an efficient lyophilized kit of THP-desIL2 for Ga-labelling at room temperature in GMP conditions, obtaining excellent in vitro and in vivo results. [ Ga]Ga-THP-desIL2 PET/CT studies in humans showed favorable dosimetry and safety, thus highlighting its potential for a wide range of clinical applications, particularly in immune-mediated diseases and cancer.
AbstractList This study aimed to develop a ready-to-use kit for Ga-labelling of interleukin-2 (IL2) facilitating PET imaging of activated T-lymphocytes. Human recombinant IL2 (hrIL2) and Aldesleukin (desIL2), conjugated with two different chelators (NODAGA and THP) were compared. Conjugated-IL2 was stored, freeze-dried at -80 °C and radiolabelled at room temperature. In vitro quality controls (iTLC, HPLC, SDS-PAGE, spectrometry and binding assays on activated T-lymphocytes) and in vivo biodistribution studies in BALB/c mice, were performed. The shelf life of the lyophilized kits was assessed up to 6 months of storage, by iTLC, HPLC and SDS-PAGE. First-in-human study was conducted in 5 volunteers by performing [ Ga]Ga-THP-desIL2 PET/CT acquisitions at several time-points, to assess biodistribution and dosimetry. Mass spectrometry showed that only one molecule of THP or NODAGA is bound to N-terminus of both IL2 proteins. The most efficient conjugation was observed for THP-desIL2. [ Ga]Ga-THP-desIL2 showed higher labelling yield (LY) (59.13 ± 2.58%), radiochemical purity (RCP) (97.91 ± 0.45%) and binding affinity to its receptor on activated T-cells (Kd = 0.584 nM/L) and a more favorable biodistribution in pre-clinical studies, with rapid kidney metabolism and lower liver uptake than [ Ga]Ga-NODAGA-desIL2 and [ Ga]Ga-THP-hrIL2. Lyophilized kit of THP-desIL2 remained stable at -80 °C up to 6 months maintaining high RCP and LY. Phase I study showed a rapid plasma clearance, renal metabolism, safety and favorable dosimetry. We developed an efficient lyophilized kit of THP-desIL2 for Ga-labelling at room temperature in GMP conditions, obtaining excellent in vitro and in vivo results. [ Ga]Ga-THP-desIL2 PET/CT studies in humans showed favorable dosimetry and safety, thus highlighting its potential for a wide range of clinical applications, particularly in immune-mediated diseases and cancer.
Author Campagna, Giuseppe
Varani, Michela
Accardo, Antonella
Morelli, Giancarlo
Lauri, Chiara
Signore, Alberto
Galli, Filippo
Bentivoglio, Valeria
Author_xml – sequence: 1
  givenname: Alberto
  orcidid: 0000-0001-8923-648X
  surname: Signore
  fullname: Signore, Alberto
– sequence: 2
  givenname: Filippo
  orcidid: 0000-0002-3439-6010
  surname: Galli
  fullname: Galli, Filippo
– sequence: 3
  givenname: Michela
  orcidid: 0000-0002-7766-9031
  surname: Varani
  fullname: Varani, Michela
– sequence: 4
  givenname: Giuseppe
  orcidid: 0000-0002-1884-9171
  surname: Campagna
  fullname: Campagna, Giuseppe
– sequence: 5
  givenname: Valeria
  orcidid: 0000-0003-4369-2281
  surname: Bentivoglio
  fullname: Bentivoglio, Valeria
– sequence: 6
  givenname: Antonella
  orcidid: 0000-0002-7899-2359
  surname: Accardo
  fullname: Accardo, Antonella
– sequence: 7
  givenname: Giancarlo
  orcidid: 0000-0002-5791-3690
  surname: Morelli
  fullname: Morelli, Giancarlo
– sequence: 8
  givenname: Chiara
  orcidid: 0000-0002-0314-5059
  surname: Lauri
  fullname: Lauri, Chiara
BackLink https://www.ncbi.nlm.nih.gov/pubmed/40590904$$D View this record in MEDLINE/PubMed
BookMark eNo9kM1KAzEUhYMo9kdfwIXkBaJ3Mr9xJ0VroeCmrkSGTHLTSZ3JlGQqVPDdHa12c-5ZfFw434Scus4hIVcR3EQA-W0A4KlgQzDIkxiYOCHjKIsEy6EQp8eew4hMQtgARAUvxDkZJZAKEJCMyddrVszl21wy63r0De7erWOcms5T28q1dWsqVW8_ZI-arlizb7d1p_Y9hjta2U7V2FolG6pq6QcQvf2Uve0clU7TbS0D0gUN_U7vqXXUdb4d4LCrNqj6cEHOjGwCXv7dKXl5fFjNntjyeb6Y3S-Z4lnesyTNq7jgBlMslJaYZpVSCQfQMjHKiFQabTIUWaVzDYCoM0wMl1EqY65BxFNyffi73VUt6nLrh21-X_57GAB-AJTvQvBojkgE5Y_s8iC7HKL8lV2K-BvbPHSe
Cites_doi 10.1016/j.ajpath.2020.05.007
10.1158/0008-5472.CAN-15-1744
10.1002/dmrr.842
10.1053/j.semnuclmed.2022.08.011
10.1080/2162402X.2016.1248014
10.1016/j.phrs.2024.107342
10.2967/jnumed.112.102644
10.1158/0008-5472.CAN-90-1241
10.1007/s11307-011-0435-y
10.4137/CGMT.S14484
10.1158/1078-0432.CCR-09-1687
10.1053/jnum.2000.8084
10.2144/03356rr01
10.1200/JCO.2015.62.2730
10.1186/s41181-019-0053-x
10.1073/pnas.1322789111
10.1158/1078-0432.CCR-13-0513
10.5167/uzh-259320
10.1111/imr.13278
10.2967/jnumed.104.022679
10.4049/jimmunol.1400550
10.1053/ejnmmi.2002.1244
10.1016/S0140-6736(87)91194-4
10.1007/s002590000151
10.1007/s00259-021-05509-w
10.2967/jnumed.123.267003
10.1007/s00259-005-0010-y
10.2967/jnumed.115.154747
10.2973/qqnmi2007.051.0352
10.1038/s41577-022-00680-w
10.1007/s00259-012-2260-y
10.3390/biom14030491
10.1084/jem.20170214
10.1007/s00259-014-2785-x
10.2337/dc14-2194
10.18632/oncotarget.25355
10.3389/fimmu.2020.01067
10.1158/0008-5472.CAN-19-0550
10.2967/jnumed.120.245583
10.1007/s00259-012-2269-x
10.1016/j.biopha.2023.117617
10.1016/j.ejnmme.2007.09.003
10.2967/jnumed.120.258278
ContentType Journal Article
Copyright 2025. The Author(s).
Copyright_xml – notice: 2025. The Author(s).
DBID AAYXX
CITATION
NPM
DOI 10.1007/s00259-025-07430-9
DatabaseName CrossRef
PubMed
DatabaseTitle CrossRef
PubMed
DatabaseTitleList PubMed
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 1619-7089
ExternalDocumentID 40590904
10_1007_s00259_025_07430_9
Genre Journal Article
GroupedDBID ---
-~C
.86
04C
06C
06D
0R~
0VY
1N0
29G
29~
2JN
2JY
2LR
2~H
36B
4.4
406
40D
5GY
5RE
5VS
6NX
78A
7RV
8UJ
95-
95.
95~
AACDK
AAHNG
AAIAL
AAJBT
AANZL
AAPKM
AARTL
AASML
AATNV
AATVU
AAUYE
AAWCG
AAYQN
AAYXX
AAYZH
ABAKF
ABBBX
ABBRH
ABBXA
ABDBE
ABDBF
ABECU
ABFSG
ABFTV
ABHQN
ABIPD
ABJNI
ABJOX
ABKCH
ABLJU
ABMNI
ABMQK
ABQBU
ABSXP
ABTEG
ABTKH
ABTMW
ABUWZ
ABWNU
ABXPI
ACAOD
ACDTI
ACGFS
ACHSB
ACHVE
ACIWK
ACMDZ
ACMLO
ACOKC
ACOMO
ACPIV
ACPRK
ACSTC
ACZOJ
ADBBV
ADHIR
ADKNI
ADKPE
ADRFC
ADTPH
ADURQ
ADYFF
ADZKW
AEFQL
AEGAL
AEGNC
AEJRE
AEMSY
AENEX
AEOHA
AEPYU
AESKC
AEVLU
AEXYK
AEZWR
AFBBN
AFDZB
AFHIU
AFJLC
AFLOW
AFOHR
AFQWF
AFRAH
AFWTZ
AGAYW
AGDGC
AGJBK
AGMZJ
AGQEE
AGQMX
AGRTI
AGVAE
AGWIL
AHAVH
AHBYD
AHIZS
AHKAY
AHMBA
AHPBZ
AHSBF
AHWEU
AHYZX
AIAKS
AIGIU
AIIXL
AILAN
AITGF
AIXLP
AJRNO
AJZVZ
AKMHD
ALIPV
ALMA_UNASSIGNED_HOLDINGS
AMKLP
AMXSW
AMYLF
AOCGG
ARAPS
ATHPR
AXYYD
AYFIA
AZFZN
B-.
BA0
BENPR
BGNMA
BHPHI
BMSDO
BSONS
CITATION
CSCUP
DDRTE
DNIVK
DPUIP
DU5
EAP
EBLON
EBS
EHN
EIOEI
EMB
ESX
F5P
FEDTE
FERAY
FFXSO
FIGPU
FNLPD
G-Y
G-Z
GGCAI
GNWQR
GQ7
HCIFZ
HF~
HG6
HMJXF
HQYDN
HRMNR
HVGLF
HZ~
IHE
IJ-
IKXTQ
IMOTQ
IWAJR
IZIGR
IZQ
I~X
I~Z
J-C
JBSCW
JCJTX
JZLTJ
KDC
KPH
LLZTM
M4Y
MA-
N9A
NAPCQ
NB0
NPVJJ
NQJWS
NU0
O9-
O9G
OAM
P19
P9S
PF0
PT4
QOK
R89
R9I
RNS
ROL
RPX
RSV
S1Z
S27
S37
SAP
SDH
SISQX
SJYHP
SMD
SNPRN
SNX
SOHCF
SOJ
SPISZ
SRMVM
SSLCW
SSXJD
STPWE
SZ9
T13
TSG
TSK
TT1
UG4
UOJIU
UTJUX
UZXMN
VFIZW
W23
W48
WK8
YLTOR
Z8Z
ZMTXR
ABRTQ
ACUHS
NPM
ID FETCH-LOGICAL-c267t-457b382fe5e8cdae56bcc4200da4fcf95afdf6e96bd7d00eed6e4f2a15a32d093
ISSN 1619-7070
IngestDate Mon Jul 21 05:59:08 EDT 2025
Thu Jul 03 08:26:35 EDT 2025
IsDoiOpenAccess false
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Keywords T-lymphocytes
[68Ga]Ga-IL2
Biodistribution
Human study
PET/CT
Language English
License 2025. The Author(s).
LinkModel OpenURL
MergedId FETCHMERGED-LOGICAL-c267t-457b382fe5e8cdae56bcc4200da4fcf95afdf6e96bd7d00eed6e4f2a15a32d093
ORCID 0000-0003-4369-2281
0000-0002-1884-9171
0000-0002-3439-6010
0000-0002-7766-9031
0000-0002-7899-2359
0000-0002-0314-5059
0000-0002-5791-3690
0000-0001-8923-648X
OpenAccessLink https://link.springer.com/content/pdf/10.1007/s00259-025-07430-9.pdf
PMID 40590904
ParticipantIDs pubmed_primary_40590904
crossref_primary_10_1007_s00259_025_07430_9
PublicationCentury 2000
PublicationDate 2025-07-01
PublicationDateYYYYMMDD 2025-07-01
PublicationDate_xml – month: 07
  year: 2025
  text: 2025-07-01
  day: 01
PublicationDecade 2020
PublicationPlace Germany
PublicationPlace_xml – name: Germany
PublicationTitle European journal of nuclear medicine and molecular imaging
PublicationTitleAlternate Eur J Nucl Med Mol Imaging
PublicationYear 2025
References V Di Gialleonardo (7430_CR25) 2012
R Tavaré (7430_CR43) 2015
A Signore (7430_CR19) 2004
M Rashidian (7430_CR42) 2017
D Loose (7430_CR17) 2008
VL Chiou (7430_CR7) 2015
A Annovazzi (7430_CR18) 2003
7430_CR24
EL van der Veen (7430_CR30) 2019
R Tavare (7430_CR41) 2016
MW Konrad (7430_CR35) 1990
JD Wolchok (7430_CR5) 2009
HA Goubran (7430_CR2) 2014
A Signore (7430_CR15) 2000
ME Raeber (7430_CR10) 2023
EL van der Veen (7430_CR28) 2020
M Chianelli (7430_CR21) 2008
K Kato (7430_CR33) 2003
A Schnell (7430_CR1) 2024
R Hernandez (7430_CR9) 2022
V Renard (7430_CR16) 2007
M Nishino (7430_CR6) 2013
R Tavare (7430_CR40) 2014
AW Glaudemans (7430_CR22) 2014
N Omidvari (7430_CR38) 2024
SA Rosenberg (7430_CR12) 2014
P Sadasivam (7430_CR31) 2024
M Namavari (7430_CR36) 2011
J Levi (7430_CR39) 2021
JJ Collier (7430_CR4) 2024
C Lauri (7430_CR8) 2023
PP van de Donk (7430_CR27) 2021
V Di Gialleonardo (7430_CR26) 2012
M Opalinska (7430_CR34) 2012
V Bentivoglio (7430_CR32) 2024
CE McCarthy (7430_CR3) 2020
A Annovazzi (7430_CR20) 2006
AK Abbas (7430_CR11) 2020
A Signore (7430_CR13) 1987
SV Hartimath (7430_CR29) 2016
A Signore (7430_CR14) 2000
A Signore (7430_CR23) 2015
J Levi (7430_CR37) 2019
References_xml – year: 2020
  ident: 7430_CR11
  publication-title: Am J Pathol
  doi: 10.1016/j.ajpath.2020.05.007
– year: 2016
  ident: 7430_CR41
  publication-title: Cancer Res
  doi: 10.1158/0008-5472.CAN-15-1744
– year: 2008
  ident: 7430_CR21
  publication-title: Diabetes Metab Res Rev
  doi: 10.1002/dmrr.842
– year: 2023
  ident: 7430_CR8
  publication-title: Semin Nucl Med
  doi: 10.1053/j.semnuclmed.2022.08.011
– year: 2016
  ident: 7430_CR29
  publication-title: Oncoimmunology
  doi: 10.1080/2162402X.2016.1248014
– year: 2024
  ident: 7430_CR4
  publication-title: Pharmacol Res
  doi: 10.1016/j.phrs.2024.107342
– year: 2012
  ident: 7430_CR25
  publication-title: JNM
  doi: 10.2967/jnumed.112.102644
– year: 1990
  ident: 7430_CR35
  publication-title: Cancer Res
  doi: 10.1158/0008-5472.CAN-90-1241
– year: 2011
  ident: 7430_CR36
  publication-title: Mol Imag Biol
  doi: 10.1007/s11307-011-0435-y
– year: 2014
  ident: 7430_CR2
  publication-title: Cancer Growth Metastasis
  doi: 10.4137/CGMT.S14484
– year: 2009
  ident: 7430_CR5
  publication-title: Clin Cancer Res
  doi: 10.1158/1078-0432.CCR-09-1687
– year: 2000
  ident: 7430_CR15
  publication-title: JNM
  doi: 10.1053/jnum.2000.8084
– year: 2003
  ident: 7430_CR33
  publication-title: Biotechniques
  doi: 10.2144/03356rr01
– year: 2015
  ident: 7430_CR7
  publication-title: J Clin Oncol
  doi: 10.1200/JCO.2015.62.2730
– year: 2019
  ident: 7430_CR30
  publication-title: EJNMMI Radiopharm Chem
  doi: 10.1186/s41181-019-0053-x
– year: 2014
  ident: 7430_CR40
  publication-title: Proc Natl Acad Sci USA
  doi: 10.1073/pnas.1322789111
– year: 2013
  ident: 7430_CR6
  publication-title: Clin Cancer Res
  doi: 10.1158/1078-0432.CCR-13-0513
– year: 2023
  ident: 7430_CR10
  publication-title: EBioMedicine
  doi: 10.5167/uzh-259320
– year: 2024
  ident: 7430_CR1
  publication-title: Immunol Rev
  doi: 10.1111/imr.13278
– year: 2004
  ident: 7430_CR19
  publication-title: JNM
  doi: 10.2967/jnumed.104.022679
– year: 2014
  ident: 7430_CR12
  publication-title: J Immunol
  doi: 10.4049/jimmunol.1400550
– year: 2003
  ident: 7430_CR18
  publication-title: EJNMMI
  doi: 10.1053/ejnmmi.2002.1244
– year: 1987
  ident: 7430_CR13
  publication-title: The Lancet
  doi: 10.1016/S0140-6736(87)91194-4
– year: 2000
  ident: 7430_CR14
  publication-title: Eur J Nucl Med
  doi: 10.1007/s002590000151
– year: 2021
  ident: 7430_CR27
  publication-title: EJNMMI
  doi: 10.1007/s00259-021-05509-w
– year: 2024
  ident: 7430_CR38
  publication-title: JNM
  doi: 10.2967/jnumed.123.267003
– year: 2006
  ident: 7430_CR20
  publication-title: EJNMMI
  doi: 10.1007/s00259-005-0010-y
– year: 2015
  ident: 7430_CR43
  publication-title: J Nucl Med
  doi: 10.2967/jnumed.115.154747
– year: 2007
  ident: 7430_CR16
  publication-title: Q J Nucl Med Mol Imaging
  doi: 10.2973/qqnmi2007.051.0352
– year: 2022
  ident: 7430_CR9
  publication-title: Nat Rev Immunol
  doi: 10.1038/s41577-022-00680-w
– year: 2012
  ident: 7430_CR26
  publication-title: EJNMMI
  doi: 10.1007/s00259-012-2260-y
– year: 2024
  ident: 7430_CR32
  publication-title: Biomolecules
  doi: 10.3390/biom14030491
– year: 2017
  ident: 7430_CR42
  publication-title: J Exp Med
  doi: 10.1084/jem.20170214
– year: 2014
  ident: 7430_CR22
  publication-title: EJNMMI
  doi: 10.1007/s00259-014-2785-x
– year: 2015
  ident: 7430_CR23
  publication-title: Diabetes Care
  doi: 10.2337/dc14-2194
– ident: 7430_CR24
  doi: 10.18632/oncotarget.25355
– year: 2020
  ident: 7430_CR3
  publication-title: Front Immunol
  doi: 10.3389/fimmu.2020.01067
– year: 2019
  ident: 7430_CR37
  publication-title: Can Res
  doi: 10.1158/0008-5472.CAN-19-0550
– year: 2020
  ident: 7430_CR28
  publication-title: JNM
  doi: 10.2967/jnumed.120.245583
– year: 2012
  ident: 7430_CR34
  publication-title: EJNMMI
  doi: 10.1007/s00259-012-2269-x
– year: 2024
  ident: 7430_CR31
  publication-title: Biomed Pharmacother
  doi: 10.1016/j.biopha.2023.117617
– year: 2008
  ident: 7430_CR17
  publication-title: EJNMMI
  doi: 10.1016/j.ejnmme.2007.09.003
– year: 2021
  ident: 7430_CR39
  publication-title: JNM
  doi: 10.2967/jnumed.120.258278
SSID ssj0018289
Score 2.4578
SecondaryResourceType online_first
Snippet This study aimed to develop a ready-to-use kit for Ga-labelling of interleukin-2 (IL2) facilitating PET imaging of activated T-lymphocytes. Human recombinant...
SourceID pubmed
crossref
SourceType Index Database
Title [68Ga]Ga-interleukin-2 for imaging activated T-lymphocytes: biochemical characterization and phase I study in normal subjects
URI https://www.ncbi.nlm.nih.gov/pubmed/40590904
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1da9swFBVZCqUvY99r94Ee1iejkdiWbO2t2Za0g_YpHYUxjGzJnVnimMQudC_7CfvLu5JsNUlX2PYiguwoRudEvrq691yE3vgBU7Du5YTBCkxCqSVvWSTIkEeSx3EgaawThU_P2PF5-OmCXvR6v9ailpo6fZv9-GNeyf-gCn2Aq86S_Qdk3aDQAZ8BX2gBYWj_CuNDOvJY7E3EIf0wEURLPyxnqvlelMQ38YPF3BYh0tkLV0Ibl1MyuwYAF9l1baPh0kLXzLKiAZlTb7bJmVZF4Bu86LwTK0Sr3SOlNnNn3qpJtQ9ndadvv7VzS62YLJbuFN8MOu-q8naP6Dw9xWXZhf5q-a164SKExMymco-1C6hy_Z_hmU1dKs-Gtd6EHmktyUub8zYpmpWqKrXu5PCpC4iFd5RdmGGjR6KBLTd0a9m3kR66whblxH49DAZk42aY0mpuiBDqhFtuqx5viW13l-6hHR_2HX4f7RyNR6MzdzClN6ht7pXJwLz1k3totxtkw9TZ2LQY42X6AN1vdx34yFLoIeqp8hHaPW0ReYx-fsEsxhPxdZtFGFiEW4iwYxHeYNE7vMYhvM0hDHBjwyF8gg2HcFFiyyHccegJOh9_nL4_Jm1pDpL5LKpJSKM0iP1cURVnUijK0iwL4b8pRZhnOacilzlTnKUykoMBGGJMhbkvhlQEvhzw4Cnql4tSPUc4C7ikikfU17UcWBYLc_Yei0jF-TAN95HXzWJSWQWWxGltm-lPoEnM9Cd8Hz2zE-3u7dA4uPPKC7R3w7mXqF8vG_UKTM06fd3C_xsVOoCc
linkProvider Library Specific Holdings
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=%5B+68+Ga%5DGa-interleukin-2+for+imaging+activated+T-lymphocytes%3A+biochemical+characterization+and+phase+I+study+in+normal+subjects&rft.jtitle=European+journal+of+nuclear+medicine+and+molecular+imaging&rft.au=Signore%2C+Alberto&rft.au=Galli%2C+Filippo&rft.au=Varani%2C+Michela&rft.au=Campagna%2C+Giuseppe&rft.date=2025-07-01&rft.eissn=1619-7089&rft_id=info:doi/10.1007%2Fs00259-025-07430-9&rft_id=info%3Apmid%2F40590904&rft.externalDocID=40590904
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1619-7070&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1619-7070&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1619-7070&client=summon